We have examined the perturbation of epidermal growth factor (EGF) receptor-receptor interactions by a monoclonal antibody (13A9) that binds to the receptor extracellular domain. While 13A9 did not inhibit EGF binding, it inhibited energy transfer between fluorescent-labeled EGF molecules bound to receptors in membranes from human A431 cells by 70-100%. This antibody also inhibited EGF-stimulated receptor dimerization in membranes as assessed by chemical cross-linking and Fab fragments of the antibody strongly inhibited the EGF-stimulated dimerization of solubilized receptors when assessed by velocity sedimentation. However, under conditions where 13A9 inhibited receptor-receptor interactions within the plasma membranes, the antibody had no effect on EGF-stimulated receptor autophosphorylation or tyrosine kinase activity toward an exogenous substrate. Moreover, although the antibody significantly inhibited receptor dimerization in A431 cells, it had no effect on EGF-stimulated changes in cytosolic free [Ca2+] or 125I-EGF uptake in these cells, or on EGF-stimulated DNA synthesis in Swiss 3T3 cells. We conclude that the dimerization of the EGF receptors in a membrane environment is not required for full activation of tyrosine kinase activity and that inhibition of the dimerization of a large fraction of EGF receptors in cells does not necessarily inhibit several EGF-mediated cellular responses.
No takes yet. Share an insight, caveat, or question.
Carraway et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: